• Renaud Felten, Florence Scher, Jean Sibilia, François Chasset, and Laurent Arnaud.
• Service de rhumatologie, hôpitaux universitaires de Strasbourg, 67200 Strasbourg, France; Université de Strasbourg, centre national de référence RESO-Lupus, 67000 Strasbourg, France; Laboratoire d'immunologie, immunopathologie et chimie thérapeutique, institut de biologie moléculaire et cellulaire (IBMC), CNRS UPR3572, 67000 Strasbourg, France. Electronic address: renaud.felten@chru-strasbourg.fr.
• Joint Bone Spine. 2019 Jul 1; 86 (4): 429-436.

AbstractThere have been many advances in the diagnosis and therapeutic management of systemic lupus erythematosus (SLE) over the past decades. Following more than eleven centuries of therapeutic uncertainty, the discovery of the therapeutic properties of glucocorticoids is without any doubt one of the most significant advance in the field of autoimmune diseases. The many progresses made by rapidly growing chemical industry of the 19th century chemistry have allowed the identification of valuable therapeutic compounds such as anti-malarials, cyclophosphamide, azathioprine, cyclosporine and later mycophenolate mofetil, which have all profoundly changed the face of the disease. A very visible consequence of this is the profound improvement in the prognosis of the disease, with 10-year survival rates of more than 90% in most dedicated centres. Following the development of biotherapies in rheumatoid arthritis, the late 20th century has slowly opened a new era for the treatment of SLE, that of targeted therapies. With the approval of belimumab in 2011 and 74 targeted therapies in clinical development, we may expect great changes in the therapeutic management of SLE. Those molecules target inflammatory cytokines or chemokines and their receptors, B cells or plasma cells, intracellular signalling pathways, B/T cells co-stimulation molecules, interferons, plasmacytoid dendritic cells, as well as various other targets of interest. Current challenges are now slowly shifting from whether some new drugs will be available to how to select the most adequate drug (or drug combination) at the patient-level.Copyright © 2018 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

29 keywords...

hide…